Evidence map›Paper›PMID 40410684›Full record

ReviewMolecular medicine (Cambridge, Mass.)2025

Mucosal implications of oral Jak3-targeted drugs in COVID patients.

Narendra Kumar, Daniel Segovia, Priyam Kumar, Hima Bindu Atti, Soaham Kumar, Jayshree Mishra

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Narendra KumarILR-College of Pharmacy, Texas A&M University Health Science Center, Kingsville, TX, USA. narendra08@tamu.edu.
Daniel SegoviaILR-College of Pharmacy, Texas A&M University Health Science Center, Kingsville, TX, USA.
Priyam KumarUniversity of Pennsylvania, Philadelphia, PA, USA.
Hima Bindu AttiILR-College of Pharmacy, Texas A&M University Health Science Center, Kingsville, TX, USA.
Soaham KumarVeterans Memorial High School, Corpus Christi, TX, USA.
Jayshree MishraILR-College of Pharmacy, Texas A&M University Health Science Center, Kingsville, TX, USA. Jayshree.mishra@tamu.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The JAK family, particularly JAK3, plays a crucial role in immune signaling and inflammatory responses. Dysregulated JAK3 activation in SARS-CoV-2 infections has been associated with severe inflammation and respiratory complications, making JAK inhibitors a viable therapeutic option. However, their use raises concerns regarding immunosuppression, which could increase susceptibility to secondary infections. While long-term adverse effects are less of a concern in acute COVID-19 treatment, patient selection and monitoring remain critical. Furthermore, adverse effects associated with oral JAK3 inhibitors necessitate the exploration of alternative strategies to optimize therapeutic efficacy while minimizing risks. This review highlights the role of JAK3 in immune and epithelial cells, examines the adverse effects of oral JAK3 inhibitors in COVID-19 and other treatments, and discusses alternative therapeutic strategies for improving patient outcomes.

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentJanus Kinase 3Janus Kinase InhibitorsAdministration, OralCOVID-19HumansSARS-CoV-2Antiviral AgentsJAK3 protein, humanJanus Kinase 3Janus Kinase InhibitorsCovid-19Jak3Keyword 1Keyword 2Keyword 3Mucosal -epithelial

Identifiers

PMID40410684
PMCPMC12100796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.